Skip to content

Author

Gabriel E. Boyle

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Abstract B001: Beyond DNA damage: What truly drives anthracycline cytotoxicity?

Anthracyclines, like doxorubicin, are cornerstone therapies against pediatric sarcomas, and are a first-line treatment for virtually all osteosarcoma patients. While doxorubicin is classified as a topoisomerase II inhibitor whose antineoplastic activity is historically attributed to DNA damage, osteosarcomas are noto...

Gabriel E. Boyle · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.